Mesoridazine Besylate

Mesoridazine besylate, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer which is effective in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses. Mesoridazine besylate is 10 [2(1-methyl 2-piperidyl) ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].

Mesoridazine Besylate is primarily indicated in conditions like Schizophrenia, and can also be given in adjunctive therapy as an alternative drug of choice in Chronic alcoholism, Hyperactivity.

Mesoridazine Besylate is contraindicated in conditions like CNS depression,Hypersensitivity to the drug.

Drowsiness and hypotension were the most prevalent side effects encountered. Side effects tended to reach their maximum level of severity early with the exception of a few (rigidity and motoric effects) which occurred later in therapy. With the exceptions of tremor and rigidity, adverse reactions were generally found among those patients who received relatively high doses early in treatment. Clinical data showed no tendency for the investigators to terminate treatment because of side effects. Central Nervous System: Drowsiness, Parkinson’s syndrome, dizziness, weakness, tremor, restlessness, ataxia, dystonia, rigidity, slurring, akathisia, motoric reactions (opisthotonos) have been reported. Autonomic Nervous System: Dry mouth, nausea and vomiting, fainting, stuffy nose, photophobia, constipation and blurred vision have occurred in some instances. Genitourinary System: Inhibition of ejaculation, impotence, enuresis, incontinence, and priapism have been reported. Skin: Itching, rash, hypertrophic papillae of the tongue and angioneurotic edema have been reported. Cardiovascular System: Serentil ® (mesoridazine besylate) produces a dose related prolongation of the QTc interval, which is associated with the ability to cause torsade de pointes-type arrhythmias, a potentially fatal polymorphic ventricular tachycardia, and sudden death (see WARNINGS). Ventricular arrhythmias and death have been reported in association with Serentil overdosage. A causal relationship between these events and Serentil therapy has not been established but, given the ability of Serentil to prolong the QTc interval, such a relationship is possible. Other ECG changes have been reported (see Phenothiazine Derivatives: Cardiovascular Effects).

While ocular changes have not to date been related to Mesoridazine besylate, one should be aware that such changes have been seen with other drugs of this class. Because of ponoible hypotensive effects, reserve parenteral administration for bedfast patients or for acute ambulatory cases, and keep patient lying down for at least one-half hour after injection. Leokopenia and/or agranulocytosis have been attributed to phenothiazine therapy. A single case of transient granulocytopenia has been associated with mesoridazine besylate. Since convulsive seizures have been reported, patients receiving anticonvulsant medication should be maintained on that regimen while receiving mesoridazine besylate.

Drug should not be given to patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

100 to 400 mg (250 (250)) As recommended. PO — The usual optimum total daily dose range . 50 mg (50 (50)) As recommended. PO — Starting dose

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

There are no studies of the coadministration of mesoridazine and other drugs which prolong the QTc interval. However, it is expected that such coadministration would produce additive prolongation of the QTc interval and, thus, such use is contraindicated (see WARNINGS and CONTRAINDICATIONS).

No storage information is recorded for this medicine yet.